Nav: Home

Researchers discover new molecules for tracking Parkinson's disease

September 21, 2020

For many of the 200,000 patients diagnosed with Parkinson's disease in the United States every year, the diagnosis often occurs only after the appearance of severe symptoms such as tremors or speech difficulties. With the goal of recognizing and treating neurological diseases earlier, researchers are looking for new ways to image biological molecules that indicate disease progression before symptoms appear. One such candidate, and a known hallmark of Parkinson's disease, is the formation of clumps of alpha-synuclein protein, and, while this protein was identified more than 20 years ago, a reliable way to track alpha-synuclein aggregates in the brain has yet to be developed.

Now, a new study published in Chemical Science describes an innovative approach for identifying molecules that can help track the progression of Parkinson's disease. Conducted by researchers in the labs of E. James Petersson, Robert Mach, and Virginia Lee, this proof-of-concept study could change the paradigm for how researchers screen and test new molecules for studying a wide range of neurodegenerative diseases.

Studying these types of protein aggregates requires new tracers, radioactive molecules that clinicians use to image tissues and organs, for positron emission tomography (PET). As a senior researcher in the field of PET tracer development, Mach and his group worked for several years with the Michael J. Fox Foundation to develop an alpha-synuclein tracer, but without data on the protein's structure they were unable to find candidates that were selective enough to be used as a diagnostic tool.

Then, with the first publication of alpha-synuclein's structure and an increase in tools available from the field of computational chemistry, Mach and Petersson started collaborating on developing an alpha-synuclein PET tracer. By combining their respective expertise in radiochemistry and protein engineering, they were able to confirm experimentally where on the alpha-synuclein protein potential tracer molecules were able to bind, crucial information to help them discover and design molecules that would be specific to alpha-synuclein.

In their latest study, the researchers developed a high-throughput computational method, allowing them to screen millions of candidate molecules, to see which ones will bind to the known binding sites on alpha-synuclein. Building off a previously published method, their approach first identifies an "exemplar", a pseudo-molecule that fits perfectly into the binding site of alpha-synuclein. Then, that exemplar is compared to actual molecules that are commercially available to see which ones have a similar structure. The researchers then use other computer programs to help narrow down the list of candidates for testing in the lab.

To evaluate the performance of their screening method, the scientists identified a small subset of 20 promising candidates from the 7 million compounds that were screened and found that two had extremely high binding affinity to alpha-synuclein. The researchers also used mouse brain tissues provided by the Lee group to further validate this new method. The researchers were impressed, and pleasantly surprised, by their success rate, which they attribute to the specific nature of their search method. "There's certainly a bit of luck involved as well," Petersson adds, "Probably the biggest surprise is just how well it worked."

The idea of using the exemplar method to tackle this problem came to first author and Ph.D. graduate John "Jack" Ferrie while he was learning computational chemistry methods at the Institute for Protein Design at the University of Washington as part of a Parkinson's Foundation Summer Fellowship. "The summer fellowship is designed to train students in new methods that can be applied to Parkinson's disease research, and that's exactly what happened here," says Petersson. "The ideas that Jack came back with formed the basis of a big effort in both my lab and Bob Mach's lab to identify PET tracers computationally."

Now, as part of a large multi-institutional grant, Petersson, Mach, Lee, and many other collaborators are poised to take the lessons learned from this finding to develop PET tracers for Parkinson's and other neurodegenerative diseases. "I really see this as being a game changer on how we do PET probe development," says Mach. "The significance is that we're able to screen millions of compounds within a very short period of time, and we're able to identify large numbers of compounds that will likely bind with high affinity to alpha-synuclein. We're also going to apply this same method to the development of other probes that are important but have presented challenges to the field."
-end-
This research was supported by National Institutes of Health( grants U19-AG062418-02, R01-NS103873, U19-NS110456, and T32AG000255), National Science Foundation (Grant DGE-1321851), and Parkinson's Disease Foundation (Fellowship PF-RVSA-SFW-1754) and by support from the Michael J. Fox Foundation

University of Pennsylvania

Related Neurodegenerative Diseases Articles:

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.
Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.
Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.
Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.
Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.
Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.
Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.
Neurodegenerative diseases may be caused by transportation failures inside neurons
Protein clumps are routinely found in the brains of patients with neurodegenerative diseases.
More Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.